Physician profile
Matthew E Snow
NPI 1114989837
$5,298.02
in general payments reported to CMS, 2019-2025
34 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,347 · 2020: $501 · 2021: $1,009 · 2022: $538 · 2023: $760 · 2024: $538 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $634.17 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $596.29 | 2019-2025 | |
| Amgen INC. | $535.06 | 2019-2023 | Repatha |
| Pfizer INC. | $439.89 | 2019-2025 | |
| Novo Nordisk INC | $406.62 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $401.96 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $326.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $297.52 | 2019-2024 | |
| Astellas Pharma US INC | $175.12 | 2019-2021 | |
| Amarin Pharma, INC. | $146.22 | 2019-2021 | |
| Biotronik INC. | $141.82 | 2021 | |
| Boston Scientific Corporation | $140.54 | 2019-2025 | Watchman Flx, Watchman Access System |
| Esperion Therapeutics, INC. | $137.87 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $134.90 | 2021-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $95.53 | 2024 | Arcalyst |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Snow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.